Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
View/ Open
Date
2017-01Author
Kollár, A
Jones, RL
Stacchiotti, S
Gelderblom, H
Guida, M
Grignani, G
Steeghs, N
Safwat, A
Katz, D
Duffaud, F
Sleijfer, S
van der Graaf, WT
Touati, N
Litière, S
Marreaud, S
Gronchi, A
Kasper, B
Type
Journal Article
Metadata
Show full item recordAbstract
Background Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy including anthracyclines. Data on the efficacy in vascular sarcomas are limited. The main objective of this study was to investigate the activity of pazopanib in vascular sarcomas.Patients and methods A retrospective study of patients with advanced vascular sarcomas, including angiosarcoma (AS), epithelioid hemangioendothelioma (HE) and intimal sarcoma (IS) treated with pazopanib in real life practice at EORTC centers as well as patients treated within the EORTC phase II and III clinical trials (62043/62072) was performed. Patient and tumor characteristics were collected. Response was assessed according to RECIST 1.1. and survival analysis was performed.Results Fifty-two patients were identified, 40 (76.9%), 10 (19.2%) and two (3.8%) with AS, HE and IS, respectively. The response rate was eight (20%), two (20%) and two (100%) in the AS, HE and IS subtypes, respectively. There was no significant difference in response rate between cutaneous and non-cutaneous AS and similarly between radiation-associated and non-radiation-associated AS. Median progression-free survival (PFS) and median overall survival (OS; from commencing pazopanib) were three months (95% CI 2.1-4.4) and 9.9 months (95% CI 6.5-11.3) in AS, respectively.Conclusion The activity of pazopanib in AS is comparable to its reported activity in other STS subtypes. In this study, the activity of pazopanib was similar in cutaneous/non-cutaneous and in radiation/non-radiation-associated AS. In addition, pazopanib showed promising activity in HE and IS, worthy of further evaluation.
Collections
Subject
Tunica Intima
Humans
Neoplasms
Hemangiosarcoma
Hemangioendothelioma, Epithelioid
Lymphatic Metastasis
Sulfonamides
Pyrimidines
Angiogenesis Inhibitors
Neoplasm Staging
Prognosis
Survival Rate
Retrospective Studies
Follow-Up Studies
Adult
Aged
Aged, 80 and over
Middle Aged
Female
Male
Research team
Clinical and Translational Sarcoma
Sarcoma Clinical Trials (R Jones)
Language
eng
Date accepted
2016-09-05
License start date
2017-01
Citation
Acta oncologica (Stockholm, Sweden), 2017, 56 (1), pp. 88 - 92